Literature DB >> 18309959

Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.

Daniel B Costa, Susan T Schumer, Daniel G Tenen, Susumu Kobayashi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18309959     DOI： 10.1200/JCO.2007.14.9039

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  50 in total

1.  Quantifying the sensitivities of EGF receptor (EGFR) tyrosine kinase inhibitors in drug resistant non-small cell lung cancer (NSCLC) cells using hydrogel-based peptide array.

Authors:  Gargi Ghosh; Xiaoliang Yan; Andrew G Lee; Stephen J Kron; Sean P Palecek
Journal:  Biosens Bioelectron       Date:  2010-08-03       Impact factor: 10.618

2.  Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.

Authors:  Daniel B Costa; Kim-Son H Nguyen; Byoung C Cho; Lecia V Sequist; David M Jackman; Gregory J Riely; Beow Y Yeap; Balázs Halmos; Joo H Kim; Pasi A Jänne; Mark S Huberman; William Pao; Daniel G Tenen; Susumu Kobayashi
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

Review 3.  Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer.

Authors:  Arjan Gower; Yisong Wang; Giuseppe Giaccone
Journal:  J Mol Med (Berl)       Date:  2014-05-23       Impact factor: 4.599

Review 4.  Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer.

Authors:  Salvatore Corallo; Ettore D'Argento; Antonia Strippoli; Michele Basso; Santa Monterisi; Sabrina Rossi; Alessandra Cassano; Carlo M Barone
Journal:  Target Oncol       Date:  2017-04       Impact factor: 4.493

Review 5.  Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer.

Authors:  Mukesh Kumar; Vinicius Ernani; Taofeek K Owonikoko
Journal:  Mol Aspects Med       Date:  2015-07-14

6.  T790M and acquired resistance of EGFR TKI: a literature review of clinical reports.

Authors:  Chunyan Ma; Shuzhen Wei; Yong Song
Journal:  J Thorac Dis       Date:  2011-03       Impact factor: 2.895

7.  Ubiquitin ligase SMURF2 enhances epidermal growth factor receptor stability and tyrosine-kinase inhibitor resistance.

Authors:  Paramita Ray; Krishnan Raghunathan; Aarif Ahsan; Uday Sankar Allam; Shirish Shukla; Venkatesha Basrur; Sarah Veatch; Theodore S Lawrence; Mukesh K Nyati; Dipankar Ray
Journal:  J Biol Chem       Date:  2020-07-15       Impact factor: 5.157

8.  Exon 19 L747P mutation presented as a primary resistance to EGFR-TKI: a case report.

Authors:  Yu-Ting Wang; Wei-Wei Ning; Jing Li; Jian-An Huang
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

9.  DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.

Authors:  Paul Yeh; Heidi Chen; Jenny Andrews; Riyad Naser; William Pao; Leora Horn
Journal:  Clin Cancer Res       Date:  2013-01-23       Impact factor: 12.531

Review 10.  Mechanisms of resistance to EGFR targeted therapies.

Authors:  Gorjan Hrustanovic; Bianca J Lee; Trever G Bivona
Journal:  Cancer Biol Ther       Date:  2013-01-28       Impact factor: 4.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.